MapLight Therapeutics (MPLT): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
4 concentrated managers hold it (−2 vs last quarter) with a median weight of 0.8%. 1 officer or director bought in 6 months.
Who owns MapLight Therapeutics?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: Catalyst4 (13D/A filed Aug 18, 2026), T. Rowe Price Investment Management (13G/A filed May 15, 2026), Forbion Growth Opportunities Fund III Cooperatief U.A. (13G filed Feb 17, 2026) and Nan Fung Group Holdings (13G filed Aug 20, 2026). Catalyst4, Inc. and Novo Holdings A/S are listed on their Form 4 filings as owners of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were Novo Holdings A/s (3.7 million shares), Iii Services B.v Fcpm (3.2 million shares) and T. Rowe Price Investment Management (2.8 million shares).
Which institutions hold the most MapLight Therapeutics shares?
Per Form 13F filings as of Jun 30, 2026:
- 1. Novo Holdings A/s: 3.7 million shares
- 2. Iii Services B.v Fcpm: 3.2 million shares
- 3. T. Rowe Price Investment Management: 2.8 million shares
- 4. Goldman Sachs Group: 1.9 million shares
- 5. Price T Rowe Associates: 1.4 million shares
- 6. BlackRock: 1.0 million shares
- 7. Nan Fung Group Holdings: 971,253 shares
- 8. 5AM Venture Management: 950,011 shares
- 9. Sanofi: 912,041 shares
- 10. State Street: 852,150 shares
Sources:13D/A by Catalyst4 (Aug 18, 2026) ↗13G/A by T. Rowe Price Investment Management (May 15, 2026) ↗13G by Forbion Growth Opportunities Fund III Cooperatief U.A. (Feb 17, 2026) ↗13G by Nan Fung Group Holdings (Aug 20, 2026) ↗All of the company's proxy statements on EDGAR ↗
With more than one share class, a 13D or 13G counts shares convertible from another class as owned, so we do not show its percentage. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Change in managers (6 → 4): 1 opened · 3 exited = −2
Net flow in the quarter: −$3.4M (−95 K shares) · bought $24.6M and sold $28.0MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.
Concentrated managers holding it
- Iii Services B.v Fcpm$116M15.4%
- Paradigm Biocapital AdvisorsNew$24.6M0.5%+0.5 pp
- Baker Bros. Advisors$13.1M0.1%
- DAFNA Capital Management$6.1M1.2%
Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.
Other relevant holders
Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.
- Novo Holdings A/sFoundation or endowment$132M7.7%
Largest holders of MPLT (all 13F filers)
- Novo Holdings A/s3.7 MFoundation or endowment0
- Iii Services B.v Fcpmconcentrated3.2 MType not verified0
- T. Rowe Price Investment Management2.8 MInvestment firm−20 K
- Goldman Sachs Group1.9 MBank or trading desk−47 K
- Price T Rowe Associates1.4 MInvestment firm+1.3 M
- BlackRock1.0 MIndex manager−315 K
- Nan Fung Group Holdings971 KType not verified0
- 5AM Venture Management950 KPrivate equity or venture capital0
- Sanofi912 KOperating company0
- State Street852 KIndex manager+513 K
- Shares
- 3.7 M
- Change
- 0
See more
- Type
- Foundation or endowment
- Value
- $132M
- Iii Services B.v Fcpmconcentrated
- Shares
- 3.2 M
- Change
- 0
See more
- Type
- Type not verified
- Value
- $116M
- Shares
- 2.8 M
- Change
- −20 K
See more
- Type
- Investment firm
- Value
- $99.7M
- Shares
- 1.9 M
- Change
- −47 K
See more
- Type
- Bank or trading desk
- Value
- $69.8M
- Shares
- 1.4 M
- Change
- +1.3 M
See more
- Type
- Investment firm
- Value
- $51.0M
- Shares
- 1.0 M
- Change
- −315 K
See more
- Type
- Index manager
- Value
- $36.7M
- Nan Fung Group Holdings
- Shares
- 971 K
- Change
- 0
See more
- Type
- Type not verified
- Value
- $34.8M
- Shares
- 950 K
- Change
- 0
See more
- Type
- Private equity or venture capital
- Value
- $34.0M
- Sanofi
- Shares
- 912 K
- Change
- 0
See more
- Type
- Operating company
- Value
- $32.7M
- Shares
- 852 K
- Change
- +513 K
See more
- Type
- Index manager
- Value
- $30.5M
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Held by institutions (13F)
Institutions (13F): 61.9% of the shares · top 10: 41.9% · in index firms: 13.6% of the institutional total
Q2 2026: 61.9%
Shares reported by the 105 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Mar 19, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- -66.0%
- Revenue (TTM)
- —
- Revenue growth
- —
- Net income (TTM)
- $-230M
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- $-175M
- Quality vs sector
- —
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Earnings quality and debt
- Operating cash flow ÷ net income (12 months)
- no datanot calculated with negative net income
- Interest coverage (operating income ÷ interest)
- no data
- Debt due within 12 months
- no data
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 1 · $65.4M
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Unregistered sale of equity securities (Item 3.02)
«Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…»
Change in directors or officers (Item 5.02)
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers
- Crinetics PharmaceuticalsCRNX · 5 managers